Segal Trials Plays Key Role in FDA Approval of COBENFY, A New Era in Schizophrenia Treatment
Barclays Adjusts Price Target on Bristol-Myers Squibb to $43 From $42, Maintains Underweight Rating
Bristol-Myers Squibb Says FDA Approves Perioperative Treatment of Neoadjuvant Opdivo in NSCLC
U.S. Food and Drug Administration Approves Perioperative Treatment of Neoadjuvant Opdivo (Nivolumab) and Chemotherapy Followed by Surgery and Adjuvant Single-Agent Opdivo for Resectable Non-Small Cell Lung Cancer (NSCLC)
Bristol-Myers Squibb Options Spot-On: On October 3rd, 367.35K Contracts Were Traded, With 802.8K Open Interest
On October 3rd ET, $Bristol-Myers Squibb(BMY.US)$ had active options trading, with a total trading volume of 367.35K options for the day, of which put options accounted for 4.31% of the total
Express News | FDA Approves Neoadjuvant/Adjuvant Nivolumab for Resectable Non-Small Cell Lung Cancer
Daily short sale tracking: Ambev SA's short volume increased by 8 million, with a short sale ratio of 19%
Ambev SA(ABEV.US) ranked top of the list had the largest change in short volume (8.35 million shares), and the short volume ratio of Corebridge Financial(CRBG.US) reached 41.46%. See more about the top 10 list of short selling volume changes in the latest trading day of the US stock market.
U.S. Tweaks 2025 Medicare Price Negotiation Process
Bristol-Myers Squibb To Go Ex-Dividend On October 4th, 2024 With 0.6 USD Dividend Per Share
October 2nd (Eastern Time) - $Bristol-Myers Squibb(BMY.US)$ is trading ex-dividend on October 4th, 2024.Shareholders of record on October 4th, 2024 will receive 0.6 USD dividend per share on
Bristol-Myers Squibb (BMY.US) collaborates with Prime Medicine (PRME.US) to develop innovative cell therapy.
Prime Medicine will receive an upfront payment of $55 million and $55 million in private equity, and is eligible to receive over $3.5 billion in milestone payments.
Bristol-Myers Squibb Options Spot-On: On October 2nd, 91,629 Contracts Were Traded, With 795.1K Open Interest
On October 2nd ET, $Bristol-Myers Squibb(BMY.US)$ had active options trading, with a total trading volume of 91,629 options for the day, of which put options accounted for 25.9% of the total
Bristol-Myers Tops Growth Chart Among S&P 500 Healthcare Stocks in Q3
This Is What Whales Are Betting On Bristol-Myers Squibb
IGM Biosciences' New Found Focus: Pivots From Cancer To Autoimmune Diseases, Names New CEO
Bristol-Myers Squibb Company (BMY) Is Driving Growth Through Strategic Acquisitions
Hold Rating on Bristol-Myers Squibb Amid Market Challenges and Strategic Execution Risks
US Federal Judge Dismisses $6.4 Billion Suit Against Bristol Myers Squibb
Bristol Myers Squibb Marks 10 Years of Global Patient Week With Community Initiatives in the Region
U.S. stock market anomaly | Prime Medicine soared about 45%, signed a research collaboration and license agreement with bristol-myers squibb.
September 30th, Gelonghui | Prime Medicine (PRME.US) surged by about 45%, reaching a peak of $5.02. On the news front, Prime Medicine signed a research collaboration and licensing agreement with Bristol-Myers Squibb, agreeing to jointly develop and commercialize multiple therapies. According to the agreement, Bristol-Myers Squibb will invest $55 million to purchase Prime's equity, and Prime will receive a $55 million upfront payment. Once certain sales and development milestones are reached, the upfront payment could exceed $3.5 billion.
Sector Update: Health Care Stocks Steady Premarket Monday